Saracatinib (SC), a SRC/ABL1 dual inhibitor, inhibits the growth of CML cells resistant or sensitive to IM, as a consequence of down regulating important survival signalling pathways (STAT5, ERK, PI3K/AKT) [1, 19]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.